Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Wednesday, 10 January 2018 23:45

Chair Letter to Shareholders

Thursday, 21 December 2017 19:16

CLINUVEL Newsletter - December 2017

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS EnglandSCENESSE® subject to further review by NICE until May 2018Leatherhead, UK and Melbourne, Australia 21 December 2017CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; XETRA: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY] today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published, with SCENESSE® (afamelanotide 16mg) not recommended for reimbursement for the ultra-orphan disorder erythropoietic protoporphyria (EPP)1, subject to NICE’s final recommendation expected in May 2018. SCENESSE® is the only approved treatment for EPP patients in Europe and is currently under review as…
Thursday, 07 December 2017 18:48

CLINUVEL Newsletter - December 2017

Tuesday, 28 November 2017 09:19

Chair's Address to the Annual General Meeting

Chair’s address to the Annual General MeetingMelbourne, Australia, 28 November 2017 Coming from the background of an ethical pharmaceutical company I had some misgivings 15 years ago of joining the board of a company with a ‘tanning’ drug. Here we are today, a genuine biopharmaceutical company having posted revenues of AUD$17.3m on a single drug used to treat an unusual orphan disorder.The pathway through the FDA to the North American market is the next peak we have to scale and this requires diligence and care with the application of additional data we have gathered from our European experience. It’s not…
Tuesday, 28 November 2017 09:12

Results of Meeting

Tuesday, 07 November 2017 19:24

Response to ASX Price Query

Page 1 of 56

Quick Links